Observational Study of Travellers Pathologies

Not Applicable

Recruiting

• Conditions: Travel-Related Illness

• Registration Number: NCT06701890
• Lead Sponsor: Institut Pasteur

Brief Summary

Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.

The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.

Detailed Description

Traveling to emerging countries is associated with a significant risk of encountering health issues specific to the destination, such as gastrointestinal and respiratory infections, malaria episodes, and road traffic accidents.These conditions are associated with behavioral, geographical, or environmental risk factors. A better understanding of these factors will enable the development of targeted recommendations to minimize travel related health issues.

The main objective of this study is to determine the incidence of pathologies occurring during travel outside the metropolitan territory.

Furthermore, two key aspects from a Public Health perspective are associated with travel and the globalization of exchanges: the acquisition of emerging pathogens or pathogens with antimicrobial resistance of concern.

To study these two aspects, the EOP study includes two sub-studies called EOP-Arbo and EOP-AMR.

* EOP-Arbo : The objective of this sub-study is to determine the risk of contracting an arboviral disease during travel, as well as the factors that may favor infection. For this, blood samples will be collected.

* EOP-AMR : The objective of this sub-study is to determine the risk of contracting an antibiotic-resistant bacteria during the trip. For this, faecal samples will be collected.

Study Timeline

• Study First Submitted: 2024-11-20
• Study First Submitted QC: 2024-11-20
• Study First Posted: 2024-11-22
• Study Start: 2024-12-09
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-30
• Last Update Posted: 2025-05-01
• Primary Completion: 2034-12
• Study Completion: 2036-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 11000

Inclusion Criteria

Not provided

Exclusion Criteria

1. For all participants in the EOP study :

   • Travel duration ≤ 3 days
   • Travel duration > 12 months
   • Person traveling as part of an expatriation without planned movement outside the settlement in the destination country
   • Person under legal protection or unable to express consent for participation

   2. For the EOP-Arbo Sub-study :

      • Individuals deemed clinically and/or biologically unfit by the investigator to undergo the blood samples required for the study.

   3. For the EOP-AMR Sub-study :

      • No specific exclusion criteria.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Determine the incidence of pathologies occurring during a travel outside the metropolitan territory.	10 years	Number of subjects who developed a pathology during the travel among participants

Secondary Outcome Measures

Name	Time	Method
For EOP-Arbo sub-study : Determine the prevalence for the occurrence of an arboviral disease (dengue, chikungunya, Zika) during the travel.	10 years	Number of arboviral diseases (dengue, chikungunya, Zika) during the travel among participants
For EOP-AMR sub-study : Determine the prevalence for the acquisition of multi-resistant bacteria (MRB) during the travel.	10 years	Proportion of subjects with multi-resistant bacteria acquired during the travel

Trial Locations

Locations (1)

Medical Center of Institut Pasteur; 🇫🇷 Paris, France